Latest research news

Researchers in London have found that new disease activity after treatment with cladribine could be connected to two factors before, and during treatment.

People with progressive MS in Australia now have the chance to join Platypus – an extension of the Octopus trial.

A phase I clinical trial in Italy showed a technique to deliver stem cells directly into the brain was feasible and safe for a small group of people with secondary progressive MS.

Researchers have now found artificial intelligence (AI) may help detect changes on MRI scans more accurately.

Tina Morris is the hundredth person to join ChariotMS, our phase 2 trial testing whether cladribine can help people with MS maintain the use of their arms and hands.

ECTRIMS is the world’s largest MS research conference. One of this year’s much discussed topics was equality, diversity and inclusion.

This week, researchers from across the globe gathered together at the world’s largest MS research conference. One of the hot topics at the conference was Epstein-Barr virus (EBV) – a common type of herpes virus.

A new study in Sweden showed 73% of participants treated with aHSCT had no progression of their MS for five years after treatment

A new study has revealed significantly fewer people are prescribed DMTs in the UK, compared to four other European countries.

The world’s first multi-arm, multi-stage (MAMS) platform trial to transform and discover treatments for MS has opened a new site in Cardiff.

A new study from the UK MS Register investigated how we can use information provided directly by people with MS to look at MS progression.

Researchers looked at the connection between heart and blood vessel health, with risk factors that we can influence, and secondary progressive MS.

Researchers have found the first genetic marker associated with a faster progression of MS.

The astrocyte is named for its star-like appearance under the microscope. And researchers from the University of Edinburgh found it could play an important role in repairing lesions in the MS brain.

Today there have been reports in the news that a common anti-histamine might be able to repair myelin in MS. We look at the evidence.

A new study from the University of Edinburgh shows myelin-making cells have different characteristics depending on where they are in the body. This could explain why myelin repair is so variable, even within one person.

Several previous studies suggested experiencing depression when you have MS could be linked to increased disability later on. But a new paper from the UK MS Register hasn’t found any evidence to support that.

A recent clinical trial, called the VIDAMS trial, tested whether high dose vitamin D could help treat people with relapsing remitting MS. In a paper published last week, results showed no effect of the supplement on relapses or new lesions on an MRI scan.

We’re excited to announce the new clinical trial we're funding, Octopus, has started recruitment at its first hospital site in London. This means the first few people with primary and secondary progressive MS have begun taking part.

A recent study using the UK MS Register found less than a third of people with MS have been offered a treatment for fatigue as part of their routine care. We’ve committed to raise funds for a new project to help address this.